Axonics® to Report Third Quarter 2022 Financial Results on October 31

Rhea-AI Summary

Axonics (NASDAQ: AXNX), a medical technology firm, will announce its Q3 2022 financial results after market close on October 31. A conference call will be held at 4:30 p.m. ET to discuss the results. Interested participants can register in advance via a provided link. The company specializes in products for bladder and bowel dysfunction and has recently achieved notable rankings in growth metrics.

Positive

• Ranked No. 1 on Deloitte Technology Fast 500™ in 2021.
• Ranked among the 500 fastest growing companies by Financial Times in 2022.

Negative

• None.

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report third quarter 2022 financial results after the close of trading on Monday, October 31.

Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. Interested parties that would like to join the conference call by telephone are required to register in advance by visiting the following link: Axonics 3Q22 registration. After registering, a confirmation email will be sent that includes the dial-in number and unique access code required to join the conference call by telephone.

For those not planning to ask a question on the conference call, the company recommends joining the live webcast, which can be accessed by visiting the following link: Axonics 3Q22 webcast. A replay of the webcast will be available shortly after the conclusion of the conference call and will be archived in the Events section of the Axonics investor relations website.

About Axonics

Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.

Axonics sacral neuromodulation (SNM) systems provide patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid^®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221010005006/en/

Axonics contact:

Neil Bhalodkar

Investor Relations

949-336-5293

ir@axonics.com

Source: Axonics, Inc.

FAQ

When will Axonics report its Q3 2022 financial results?

Axonics will report its Q3 2022 financial results after the market closes on October 31, 2022.

What time is the Axonics Q3 2022 conference call?

The Axonics Q3 2022 conference call will take place at 4:30 p.m. Eastern Time.

How can I join the Axonics conference call?

To join the Axonics conference call, you must register in advance through the provided link.

What products does Axonics develop?

Axonics develops products for treating bladder and bowel dysfunction, including sacral neuromodulation systems and Bulkamid®.

What market does Axonics primarily serve?

Axonics primarily serves the U.S. and European markets for adult bladder and bowel dysfunction.